Abstract: Chemotactic cytokines (chemokines) are a family of small proteins inducing directed cell migration (chemotaxis), via specific G-protein coupled receptors. Initially described as molecules regulating leukocyte recruitment at sites of inflammation, in the last decade, it has become increasingly clear that chemokines mediate several other functions and therefore are more than simple traffick controllers. Chemokines are produced by many different cell types, including tumor cells. Indeed, tumors are major producer of chemokines and have represented an invaluable source for their identification and characterization. In the tumor microenvironment chemokines are crucial regulators of the levels of tumorinfiltrating leukocytes. In addition, these mediators control a variety of biological activities, such as production and deposition of collagen, activation of matrix-digesting enzymes, stimulation of cell growth, inhibition of apoptosis and promotion of neo-angiogenesis. The expression of chemokines, therefore, is of potential advantage for tumor cells and may endow them with enhanced ability to proliferate and disseminate. The complex network of chemokines and their receptors in the tumor microenvironment is currently the object of an intense investigation aimed at targeting these molecules for therapeutic interventions.
Chemokines eponymous function is represented by the induction of leukocyte motility, such as during the recruitment of immune-competent cells into sites of inflammation or positioning in secondary lymphoid organs. Chemokines are a family of small (8-10 KDa) secreted proteins characterized by the presence of cysteine bonds at the N-terminal loop. This large family comprises fifty members identified so far [1] [2] [3] [4] [5] [6] . Based on the cystein motif, different subfamilies: CXC, CC, C and CX3C have been classified (Table 1) . In general, CXC chemokines attract neutrophils and lymphocytes, whereas chemokines belonging to the CC family act primarily on monocytes, but they can also attract lymphocytes, basophils and eosinophils. CX3C and C chemokines act on monocytes/lymphocytes and on lymphocytes only, respectively. Chemokine production can be constitutive or inducible by environmental stimuli. While constitutive chemokines usually control the homeostatic trafficking of leukocytes under steady state conditions, inducible chemokines are produced under conditions of inflammation and immune reactions.
Chemokine involvement is not limited to immunity and inflammation. Expression of these mediators and their receptors is relevant in several types of human pathologies including cardiovascular diseases, transplantation, neuroinflammation, HIV-associated diseases and neoplasia. Since their discovery, the field of chemokines was strongly connected to cancer biology. This connection is illustrated by the identification of Monocyte Chemotactic Protein-1, now called CCL2, in culture supernatants of tumor cell lines [7] . The role of chemokines in tumor biology has dramatically developed in the last decade and has expanded from the regulation of leukocyte attraction within the tumor mass to the promotion of tumor cell survival, proliferation and dissemination. In this chapter we will review the current knowledge on the field of chemokines and their relationship with cancer biology.
TUMORS PRODUCE CHEMOKINES
In the tumor microenvironment chemokines are produced both by stromal cells (fibroblasts, endothelial cells and infiltrating leukocytes) and by the tumor itself. Chemokines interact with seven transmembrane domain, G-protein coupled receptors. Ten CC (CCR1-10), six CXC (CXCR1-6), one CX3C (CX3CR1) and one XC (XCR1) receptors have been identified [3, 5] . Receptor expression is a crucial determinant of the spectrum of action of chemokines. Receptor transcription, as well as receptor signalling, is tightly regulated during cell differentiation and activation.
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immunization and gene modification, indicate that CCL2 plays a pivotal role in the recruitment of monocytes in neoplastic tisues, as discussed below [9] [10] [11] .
by breast carcinoma and melanoma [12, 13] . In breast cancer CCL5 expression by tumor cells correlates with a more advanced stage of disease, suggesting that CCL5 may be involved in breast cancer progression [13, 14] . Melanoma is probably the most studied cancer type in which CXC chemokines and in particular CXCL1 and related molecules (CXCL2, CXCL3, CXCL8 or IL-8) have been demonstrated to play a role in tumor progression [15] . They do so by A variety of other chemokines have been detected in neoplastic tissues as products of tumor cells or stromal elements. These include CCL5, CXCL12, CXCL8, CXCL1, CXCL13, CCL17 and CCL22. CCL5 is produced direct stimulation of neoplastic growth, promotion of inflammation and induction of angiogenesis. CXCL1 was initially identified and purified from supernatants of melanoma cell lines and characterized as an autocrine growth factor [16, 17] have primarily pro-tumor functions [10, 38] . TAM produce several factors that can promote angiogenesis, such as basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and several proteases (Fig. 2) . They also possess pro-coagulant activity through fibrin deposition, which indirectly enhances blood vessel formation. Indeed it was observed that the density of blood microvessels correlates with the extent of macrophage infiltration in breast cancer [39, 40] . TAM are also a source of IL-10 and PGE 2 , two potent immuno-modulating molecules contributing to immunosuppression [10, 41, 42] . On the basis of this functional profile TAM have been considered to be M2 type macrophages, like macrophages activated by Th2-cytokines and IL-10 [10]. A recent review of the prognostic significance of TAM levels in human tumors concluded that in 10 of 15 studies macrophage infiltration was associated with worse prognosis [43] .
Autocrine and paracrine expression of CCL20 has been reported in pancreatic cancer [24] . CXCL13 is a B cell chemokine and is highly expressed in Helicobacter pyloriinduced lymphoma [25] . A role for CXCL13 in the localization of tumor cells has been suggested.
In accordance with the potential dual role of TAM, the gene transfer of CCL2 into tumors had contrasting effects. At least three reports indicated reduced tumorigenicity [44] [45] [46] . The results of another study pointed to an opposite effect: the number of spontaneous lung metastases was augmented in animals injected with CCL2-transfectants compared to those injected with parental cells [47, 48] . The impact of CCL2 on tumor growth in a nontumorigenic melanoma system revealed a biphasic effect. Low-level CCL2 secretion, with "physiological" accumulation of TAM promoted tumor formation, while high CCL2 secretion resulted in massive macrophage infiltration into the tumor mass and in its destruction [48] . Similarly, a high inoculum of CCL2-transfected melanoma cells showed retarded tumor growth, while a small inoculum was more tumorigenic [38] . These results are consistent with the "macrophage balance" hypothesis [10, 29].
As mentioned above, chemokines can be classified as constitutive or inducible. Tumors are generally characterized by the constitutive expression of chemokines belonging to the inducible realm. The molecular mechanisms accounting for constitutive expression have been defined only for CXCL1 and involved NFκB activation. Melanoma cells display high expression of NF-κB-inducing kinase (NIK) [26] and this phenotype is responsible for constitutive activation of IκB kinase and MAPK signaling cascades, as well as for constitutive activation of NF-κB [27, 28] . This may represent a general mechanism underlying constitutive expression of inflammatory chemokines in tumors.
TUMOR-DERIVED CHEMOKINES ATTRACT BLOOD LEUKOCYTES: COMPLEX RELATION-SHIP BETWEEN LEUKOCYTES AND NEO-PLASTIC CELLS
As mentioned above, in addition to being a target for chemokines, TAM are a source of a selected set of these mediators (CCL2, CCL17, CCL18, CCL22) (Fig. 2) . CCL18 was recently identified as the most abundant chemokine in human ovarian ascites fluid [49] . When the source of CCL18 was investigated, it was tracked to TAM, with no production by ovarian carcinoma cells. CCL18 is a CC chemokine produced constitutively by immature DC and inducible in macrophages by IL-4, IL-13 and IL-10. Since IL-4 and IL-13 are not expressed in substantial amounts in ovarian cancer, it is likely that IL-10, produced by tumor cells and macrophages themselves, accounts for CCL18 production by TAM. CCL18 is an attractant for naive T cells by interacting with an unidentified receptor [3, 5] . Attraction of naive T cells in a peripheral microenvironment dominated by M2 macrophages and immature DC is likely to induce T cell anergy.
Tumors are composed of cancer and stromal cells, which sometimes are very developed and can even outnumber neoplastic cells. Besides fibroblasts and endothelial cells, leukocytes (especially macrophages and T lymphocytes) are the most represented cell types.
Monocyte-Macrophages
Tumor-Associated Macrophages (TAM) derive from monocytic precursors circulating in the blood [29] . Several studies have indicated that CCL2 is primarily responsible for the recruitment of monocytes at the tumor site. Indeed, CCL2 levels correlated with the abundance of TAM in several types of adenocarcinoma, including ovarian, breast and pancreas [30] [31] [32] [33] [34] [35] . Interestingly, CCL2 production has been detected also in TAM, indicating the existence of an amplification loop for their recruitment. [34] Other CC chemokines related to CCL2, such as CCL7 and CCL8 are also produced by tumors and shown to recruit monocytes [36] .
Neutrophils
CXCL8 and related chemokines act primarily on neutrophils. In spite of constitutive production of these ligands by tumor cells, neutrophils are not a major and obvious constituent of the leukocyte infiltrate. However, these cells, though present in minute numbers, may play a key role in triggering and sustaining the inflammatory cascade, for instance by releasing angiogenic molecules [50] .
TAM have an ambiguous role in their relationship with tumor cells, as described in the macrophage balance hypothesis ( Fig. 1) [10, 29, 37] . Although they can potentially display tumor cytotoxicity, they are believed to Interestingly, IL-4 and IL-13 render monocytes exquisitely sensitive to CXCL8 and CXCL1 [51] . Therefore, in the tumor microenvironment, where IL-4/IL-13-producing, polarized type II T cells can be present, CXCL8 and related chemokines may contribute to guide the positioning and to regulate the function of macrophages.
be an important factor for IL-12-mediated anti-tumor response through the recruitment and activation of CD8 lymphocytes [58] and NK cells [59] . The chemokine CCL21 recruits dendritic cells and lymphocytes (naive T, NK cells and a subset of memory T cells), and displays antineoplastic effects when transduced in tumor cells [60] [61] [62] or injected locally [63] . Similar results were reported for CCL19, which shares with CCL21 the same receptor CCR7 [64] . Lymphocytes Most of our knowledge on the role of chemokines in the recruitment of T and NK cells is derived fron studies using chemokine-transfected tumor cells. Trasduction of CCL5 in tumor cells resulted in loss of tumorigenicity due to activation of anti-tumor immunity [52] . Similar activity was shown by CCL3. These ligands of CCR5 are expressed, for instance, in nasopharingeal and ovarian carcinoma and have been proposed to regulate T cell infiltration [30, 52] . Despite these evidences, in vivo expression of CCL5 is associated with advanced disease in breast and cervical cancer [13, 53] .
Chemokines are part of amplification and regulation systems of polarized T cell responses. Some chemokines may enhance innate and specific host immunity against tumors but on the other hand other chemokines may contribute to escape from the immune system, by recruiting Th2 effectors and regulatory T cells [65, 66] . Work in genemodified mice has shown that CCL2 can orient specific immunity in a Th2 direction. Although the exact mechanism for this action has not been defined, it may include stimulation of IL-10 production in macrophages [67] .
Expression of CXCL9 has been associated with heavy infiltration of T lymphocytes in human melanoma [54] and in mouse tumor models [55] [56] [57] . CXCL10 was reported to
Reed-Sternberg cells in Hodgkin's lymphoma have been shown to express CCL22 and CCL17 [68, 69] . These chemokines recognize CCR4 which is preferentially expressed on Th2 lymphocytes and on T regulatory cells (Treg) [2, 70] . Interestingly, in the same tumor, stromal cells produce CCL11, which attracts eosinophils and Th2 cells. Therefore, in this human tumor, neoplastic elements and stroma use complementary tools to recruit immunocompetent cells associated with polarized type II responses, unable to mediate anti-tumor immunity.
Dendritic Cells
It has been clearly shown that chemokines tightly control the tissue trafficking of myeloid dendritic cells (DC) in their migration to secondary lymphoid organs [73] [74] [75] [76] [77] . Chemokines are also involved in the recruitment of DC at the tumor site [78, 79] . Although usually rare cells, DC have been detected in several tumor types, including lung, prostate, nasopharynx, kidney, thyroid, breast, ovary carcinoma and melanoma [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] . While TAM are, usually, dispersed evenly within the tumor mass, tumor-associated DC (TADC) localize in specific areas. In papillary carcinoma of the thyroid, DC were found at the invasion edge of the tumor [85] . In breast carcinoma, DC with a mature phenotype (DC-LAMP+) were localized in peri-tumoral areas, while immature DC were inside the tumor [80] . A few chemokines are more restricted for DC. CCL20 interacts with CCR6, a receptor expressed by Langerhans cells but not by monocyte-derived DC. Infiltration of Langerhans-like DC, positive for the marker Langerin, was noted in breast cancer expressing CCL20 [80] .
In the same vein of driving into tumors polarized Th2 cells, the oncogenic virus human herpesvirus 8 (HHV8], involved in the pathogenesis of Kaposi's sarcoma and hematological malignancies, encodes three CC chemokines (vMIPI, II and III) which interact with CCR3, CCR4 and CCR8 expressed on Th2 cells and T regulatory cells [70] . Consistently with these in vitro observations, Kaposi's sarcoma is infiltrated by CD8+ and, to a lesser extent, CD4+ cells with a predominant Th2 phenotype. Therefore, HHV8 virus-encoded chemokines represent a strategy to subvert antiviral/antitumor immunity by favouring the recruitment of inefficient cells and cells with suppressive activity.
In addition to viral chemokines, HHV8 encodes for a chemokine receptor homologue, ORF74, also known as KSHV vGPCR, showing similarity with CXCR2 [71, 72] . This receptor triggers a constitutive signal which is further increased by CXCL8 and CXCL1, providing a good example of a direct role of chemokines and receptors in neoplastic transformation. Indeed, over-expression of KSHV vGPCR alone resulted in the development of lesions resembling Kaposi's sarcoma [71] .
The presence of Plasmacytoid DC (P-DC), a distinct DC subset of lymphoid origin, is a recent finding. P-DC have been shown to accumulate in breast metastatic lymph node [90] and in ovarian cancer in correlation with the expression of CXCL12 to which they respond [89] . Primary melanoma are infiltrated with both myeloid and P-DC [91, 92] .
The significance of active recruitment of antigenpresenting cells in the tumor, especially whether it is a sign of active immune response, is not clear. DC are well equipped to pick up tumor antigens and cross-present them to T lymphocytes, as documented by several studies [77, 93, 94] . However DC can also potently induce tolerance [95, 96] and, as mentioned above, the tumor microenvironment contains immuno-suppressive factors that have been shown to hamper dendritic cell differentiation and activation (Fig.  3) .
aggressive neoplastic behaviour. For example, t-PA and u-PA and their respective receptors, annexin II and u-PAR, were demonstrated to contribute to the invasive behaviour of pancreatic cancer [103] . MMP-2 expression is increased in several tumors and strongly correlates with nodal status and tumor stage [104] . Chemokines are potent inducers of enzymes and receptors which degrade the extracellular matrix and favour tumor invasion. In a gene expression analysis, the chemokine CCL5 specifically induced gene expression of various MMPs, especially MMP9, along with the uPA receptor [105] .
In several tumor models where chemokine-induced tumor regression was established, the presence of DC was documented, but their exact role has not been investigated. The chemokines involved in these studies included CCL7, CCL16, CCL21 CCL20, CCL19 and CXCL12 [60] [61] [62] [63] [64] [97] [98] [99] . Therefore the role of intra-tumoral DC in the establishment of anti-tumor immunity, or in the induction of tolerance, remains to be elucidated.
Macrophages can produce proteases and strong evidence demonstrates that chemokines activate TAM to release MMPs in the tumor micro-environment (Fig. 2) . In particular, MMP9 derived from hematopoietic cells of host origin, has been shown to contribute to skin carcinogenesis [100] . In addition, MMP9 has complex effects beyond matrix degradation, including promotion of angiogenesis and release of growth factors [106] .
ROLE OF CHEMOKINES IN TUMOR SPREAD AND PROGRESSION
Angiogenesis is a key event in tumor growth and progression. Chemokines have a major impact on the regulation of neovascularization in tumor tissues. The NH2-terminus of several CXC chemokines contains a highly conserved amino acid motif (Glu-Leu-Arg: ELR motif), which immediately preceeds the first cystein [107] [108] [109] . ELR+ chemokines have potent angiogenic activity. The angiogenic members include CXCL1 through CXCL8, with the exception of CXCL4. These chemokines act through a common receptor, CXCR2. Although some ELR+ It has long been known that tumor-derived proteases can cleave the extra-cellular matrix molecules and lead to the dissolution of the basement membrane, thus facilitating the process of tumor cell invasion. A variety of proteolytic enzymes, in particular the tissue type plasminogen activator (t-PA), the urokinase-type plasminogen activators (u-PA) and the large family of matrix-metalloproteinases (MMPs) have been implicated in this degradation [100] [101] [102] . The activity of these enzymes has been associated with more chemokines bind both CXCR1 and CXCR2, it is widely accepted that only CXCR2 mediates the angiogenic activity and, accordingly, endothelial cells express only CXCR2 [110] . Another important ligand-receptor pair is CXCL12 and CXCR4. Even if CXCL12 is a non-ELR chemokine, its activity has been implicated in neo-angiogenesis [111, 112] .
Uneven vascularization and hypoxia are characteristics of neoplastic tissues. TAM accumulate preferentially in the poorly vascularized regions of tumors with low oxigen tension. Under hypoxic conditions TAM are stimulated to express hypoxia-inducible genes, such as VEGF, bFGF and CXCL8. Therefore, macrophages recruited in situ represent an indirect pathway of amplification of angiogenesis, in concert with angiogenic molecules directly produced by tumor cells.
The importance of ELR+ chemokines in supporting angiogenesis during the neoplastic progression has been established in a variety of tumor cell types, including prostate and ovarian carcinoma and NSCLC [113] [114] [115] [116] .
Table 2. Regulation of Angiogenesis by Chemokines
Both in mouse tumor models and in surgical specimens obtained from tumor patients, expression of CXCL5 and CXCL8 was associated with increased neovascularization and inversely correlated with survival. Conversely, depletion of CXCL5 resulted in attenuation of tumor growth and angiogenesis. The finding of the unique use of CXCR2 receptor, despite the redundancy of ELR+ chemokines, provides a good opportunity to target this receptor for therapeutic interventions. On the other hand, another series of CXC chemokines lacking the ELR motif (non-ELR) are characterized by the ability to block or inhibit angiogenesis.The angiostatic members are CXCL4, CXCL9, CXCL10 and CXCL11. The three latter chemokines are interferon-inducible, and their biological functions are directly relevant to the function of Th1 stimulating cytokines, like IL-12, IL-18 and IL-23, that induce the production of IFNgamma [109] . CXCL9, CXCL10 and CXCL11 bind the CXCR3 receptor [1, 108] . Recent observation has demonstrated that CXCR3 exists in two different isoforms: CXCR3A and CXCR3B, which differ in their NH2 terminus [117] CXCR3B, which is more expressed than CXCR3A in endothelial cells, appears to mediate the angiostatic activity of IFN-inducible chemokines. In addition, CXCL4 was shown to bind to CXCR3B [117] . 
TUMOR CELLS EXPRESS CHEMOKINE RECEPTORS
Chemokines act through specific 7-transmembrane receptors coupled to G proteins [1] . While the expression of chemokines in human and experimental tumors has been the object of intense investigation, the expression of chemokine receptors has been pursued to a much lesser extent, until very recently.
Non-ELR CXC chemokines have been shown to inhibit angiogenesis in several tumor models. Over-expression of CXCL9 and CXL10 in tumor cells leads to spontaneous tumor regression in lymphoma cells [118, 119] , NSCLC [120] and melanoma [121] .
Earlier studies already pointed out that tumor cells express functional chemokine receptors. Some tumor cell lines migrated in response to CXCL8 and related chemokines, and antibodies against CXCR2 were able to inhibit the growth of melanoma cells in vitro [18] . Other inflammatory chemokines have been tested and induced motility of malignant cells of hematopoietic and epithelial origin [122, 123] . The most potent chemoattractants for human breast adenocarcinoma cell lines were CCL3, CCL4, CCL5 and CCL2.
Therefore, the balance of ELR+ vs. non-ELR chemokines produced in the tumor microenvironment may determine the degree of angiogenesis surrounding and inside the tumor tissue and the consequent tumor progression.
Macrophages play a central role in tissue remodeling and repair during ontogenesis and adult life. They exert a dual influence on blood vessel formation and function: on the one hand macrophages produce molecules that are proangiogenic, on the other hand they can express antiangiogenic molecules and damage the integrity of blood vessels. In general, in the tumor micro-environment, the proangiogenic functions of TAM prevail (Fig. 1) . TAM produce a host of growth factors which affect tumor cell proliferation, angiogenesis, and the deposition and dissolution of connective tissues. In several studies, TAM accumulation in human cancer has been associated with high neovascularization and with the production of angiogenic factors such as VEGF and platelet-derived endothelial cell growth factor, fibroblast and epidermal growth factor (EGF, FGF), and chemokines [10, 40, 43] .
Breast carcinoma cells express also CXCR4, the receptor for CXCL12, and this receptor has been recently implicated in the process of metastasis [124] . Since then, many other tumors of different histologies have been evaluated and shown to express chemotactic receptors ( Table 3) .
Although cancer cells may express different receptor repertoire, the most common receptor is, by far, CXCR4. Several different tumor types of hematological, epithelial and mesenchimal origin express this receptor. For instance CXCR4 was found in acute lymphoblastic and myeloblastic leukemia, in non-Hodgkin lymphoma, in tumors derived from the ovaries, lung, kidney, pancreas and prostate, as well as in melanoma, neuroblastoma and rhabdomyosarcoma [9] . and that these receptors may be implicated in the process of distant metastasis and even organ specific metastasis. In addition, chemokines may deliver growth signals to tumor cells and therefore may be directly involved in their survival and progression. Several drugs, targeting the chemokine system, are currently being tested in inflammatory and autoimmune diseases and could be useful to treat cancer patients. Some of these drugs are chemokine antagonists and prevent the binding and/or the signalling of the right ligand through its specific receptor. Recent pre-clinical studies have reported anti-cancer activity of chemokine receptor antagonists, in several murine cancer models. An interesting study recently reported that CXCR4 is expressed in several types of malignant brain tumors [134] . In cells from adult glioblastoma and pediatric medulloblastoma, CXCR4-CXCL12 signalling induced chemotaxis and enhanced proliferation and survival [135] . When tested in vitro in cell cultures, the selective CXCR4 antagonist (AMD 3100) was shown to reverse these effects. When AMD 3100 was used to treat mice bearing intracranial glioblastoma or medulloblastoma, tumor burden was sigificantly smaller in AMD 3100-treated animals [135] . AMD 3100 has been originally tested in HIV patients as CXCR4 is one of the major receptor for the virus, and showed to have a good safety profile.These results provide a scientific rationale for the clinical evaluation of AMD 3100 in malignant brain tumors. In addition to CXCR4, other receptors have been detected. CCR6 and its ligand CCL20 were reported in human pancreatic cancer [24] . Melanoma cells express CCR7, (receptor for CCL19 and CCL21, two chemokines found in lymph nodes) [124] , as well as CCR10 (receptor for CCL27, a chemokine found in the skin) [124] . Gastric tumors express CCR7 and this receptor was associated with lymph node metastasis and poorer prognosis in two different studies [125, 126] . In addition to CXCR4 [127] [128] [129] , NSCLC may be positive for CCR7. In one retrospective analysis of patients with NSCLC, expression of CCR7 correlated with increased lymph node metastatic involvement [130] . These results found further support in experimental tumor models: transduction of tumor cells with CCR7 conferred improved ability to metastasize to regional lymph nodes [131] , while CXCR4-transfected celle preferentially migrated to the lung [132] .
In a model of non-small-cell lung cancer, immunodeficient mice inoculated with CXCR4-positive human NSCLC had lower organ metastasis if mice were injected with antibodies to CXCL12 [136] . Anti-CXCR4 and anti-CXCL12 also delayed tumor growth and reduced tumor mass in a model of non-Hodgkin's lymphoma in a NOD/SCID mice [137] . In another study, anti-CXCR4 antibodies inhibited the spread of breast cancer xenograft to lymph nodes [124] .
Breast cancer cells express also the chemokine CCL5 and the leukocyte infiltrate express the corresponding receptors CCR1 and CCR5. In murine breast cancer, treatment of mice with Met-CCL5, a CCR1/CCR5 receptor antagonist, significantly reduced the volume and weight of tumors. Furthermor, this treatment strongly decreased the total number of tumor-infiltrating macrophages, supporting the hypothesis that macrophages contribute to tumor development [138] .
Overall these results support the concept that chemokines could direct tumor cell migration in vivo: malignant cells bearing chemokine receptors on the cell surface would be endowed with the capability to respond to chemokine gradient and selectively migrate to specific organs where the chemokine is present.
Several lines of evidence show that the chemokine CXCL12 may also be involved in promoting tumor cell survival and growth. In several types of cancer, including glioma, melanoma, NSCLC, renal and thyroid, CXCL12 can stimulate tumor proliferation and/or survival of CXCR4-expressing tumor cells [9] . Production of CXCL12, both at mRNA and at protein level, has been detected in several CXCR4-expressing tumors, thus suggesting a possible autocrine or paracrine loop of growth.We recently reported that CXCR4 is frequently expressed in human pancreatic cancer cells and that CXCL12, in addition to enhancing motility and invasion, promotes their proliferation and has anti-apoptotic effects [133] .
An original strategy to inhibit chemokine and receptor binding is to prevent their cell surface expression. Cells transfected with a modified CXCL12 bearing an endoplasmic reticulum (ER) sequence (KDEL), retained both ligand and receptor (CXCR4) in the ER, thus preventing CXCR4 from reaching the cell surface. When a T cell hybridoma was transfected, the CXCR4-negative cells failed to disseminate to multiple organs upon intravenous injection, indicating a decisive role for CXCR4 in the dissemination of hematopoietic malignancies [139] .
Another example comes from colon carcinoma cells transfected with the ER-retention sequence. As a matter of fact, CXCR4-deficient cells did colonize the lungs to the same extent as control cells, however, they proliferated significantly less and did not expand [140] . Once more,
THERAPEUTIC POTENTIAL
An increasing number of studies have clearly shown that several types of cancers express various chemokine receptors, these results underline the important role of CXCL12 in the survival and proliferation of cancer cells. The chemokine network definitely affects tumor development. Therefore, chemokines and their receptors are attractive targets of therapeutic interventions. Receptor or ligand antagonists are being developed and actively investigated. In several pre-clinical studies, these molecules have shown activity both as inhibitors of leukocyte recruitment, as well as inhibitors of metastatic spreading. These studies provide a scientific rationale for the use of anti-chemokine or anti-receptor agents in human cancer. 
